Raquel Hontecillas
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$3.9MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $3.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 13, 2026 | NIH | SBIR Phase I Novel Immunoregulatory Therapeutics for Bacterial Gastritis | $314K | Biotherapeutics, Inc. |
| Aug 5, 2025 | NIH | SBIR Phase I Next-Gen Oral Therapeutics for Concomitant Clostridioides difficile Infection and IBD | $314K | Biotherapeutics, Inc. |
| Jun 27, 2024 | NIH | SBIR Phase I Comparative Efficacy of Therapeutics for Clostridioides difficile Infection | $300K | Biotherapeutics, Inc. |
| Jun 28, 2021 | NIH | SBIR Phase II Effects of Abscisic Acid on Insulin Sensitivity | $420K | Biotherapeutics, Inc. |
| Jun 11, 2021 | NIH | SBIR Phase I The First LANCL2-based therapeutic for influenza | $300K | Biotherapeutics, Inc. |
| Sep 1, 2020 | NIH | SBIR Phase I The First Pomegranate Seed Oil-Containing Medical Food for Gut and Immune Health | $295K | Biotherapeutics, Inc. |
| Jul 1, 2020 | NIH | SBIR Phase II Effects of Abscisic Acid on Insulin Sensitivity | $1.4M | Biotherapeutics, Inc. |
| Jul 1, 2019 | NIH | SBIR Phase I Development of Antibiotic-Free Clostridium difficile Therapeutics | $300K | Biotherapeutics, Inc. |
| Apr 22, 2019 | NIH | SBIR Phase II Effects of Abscisic Acid on Insulin Sensitivity | $282K | Biotherapeutics, Inc. |
Peer ranks
Federal funding#417
Awards as PI#151
Patents#273
Companies
- Biotherapeutics, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.